Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: TechSci Research | PRODUCT CODE: 1361560

Cover Image

PUBLISHER: TechSci Research | PRODUCT CODE: 1361560

Medical Cannabis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Product Type, By Active Ingredient, By Distribution Channel, By Application, By End User Industry, By Region and Competition

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4900
PDF and Excel (Multi-User License)
USD 5900
PDF and Excel (Custom Research License)
USD 8900

Add to Cart

We offer 8 hour analyst time for an additional research. Please contact us for the details.

Global medical cannabis market is expected to register a CAGR of 14.62% and reach USD 47.58 billion by 2028. This is attributed to the growing government fundings, increase in research and development activities (R&D), and growing acceptance across the world. The medical cannabis market is a rapidly growing industry that is gaining acceptance and legal recognition in many countries around the world.

Medical cannabis refers to the use of the cannabis plant or its extracts to treat a range of medical conditions, including chronic pain, nausea, seizures, and anxiety, among others. The market for medical cannabis includes a wide range of products, including dried cannabis flower, oils, capsules, tinctures, and edibles. These products can be administered in different ways, such as smoking, vaporizing, or ingestion, depending on the patient's needs and preferences. One of the main factors driving the growth of the medical cannabis market is increasing public acceptance of cannabis as a legitimate medical treatment option. As more research is conducted into the medical properties of cannabis and more patients report positive outcomes from using cannabis to manage their conditions, demand for medical cannabis products is growing. In Australia, medical cannabis was legalized in 2016, and the number of medical cannabis prescriptions has increased from 1,000 in 2017 to over 100,000 in 2021, according to the surveys conducted by Therapeutic Goods Administration.

The medical cannabis market is benefiting from advancements in cannabis cultivation and production techniques, which are leading to higher-quality products and greater consistency in dosing and potency. The legalization of medical cannabis has made it easier for patients to access this treatment option, especially in places where it was previously illegal. A study published in JAMA Internal Medicine found that states with medical cannabis laws had a 25% lower opioid overdose mortality rate compared to states without medical cannabis laws.

Hence, the medical cannabis market is expected to continue to grow as more patients and healthcare professionals recognize the potential benefits of cannabis as a medical treatment option and as more countries legalize medical cannabis use. This advancements and legalization of medical cannabis in different countries is likely to boost the medical cannabis market in the forecast period.

Legalization of Medical Cannabis to drive the Medical Cannabis Market Growth

The medical cannabis market has been rapidly growing in recent years due to various factors such as changing public attitudes towards the medical cannabis, patient testimonials, and opioid crisis. The legalization of medical cannabis in many countries and states has led to increased availability and accessibility of cannabis for medical use. This has helped to create a legal framework for the production, distribution, and consumption of medical cannabis products, making it easier for patients to access them. Also, there is growing acceptance and awareness about the potential benefits of medical cannabis in treating a wide range of medical conditions such as chronic pain, anxiety, and epilepsy. This has led to increased demand for medical cannabis products, and more people are willing to try them as a potential alternative to traditional medications. As more research is conducted on the potential health benefits of medical cannabis, more evidence is emerging to support medical cannabis use in the treatment of various medical conditions. This has helped to increase the credibility of medical cannabis as a legitimate treatment option, which in turn has encouraged more patients to consider using it. Therefore, the growing occurrences of chronic diseases across the globe is influencing the growth of the global medical cannabis market in the coming years

Legalization increases the number of patients who can access medical cannabis products. When medical cannabis is illegal, patients may be forced to obtain it from the black market, which can be risky and unsafe. Legalization ensures that patients have access to legal and regulated products, which can help to improve the quality of their healthcare. In addition to improving access and safety, legalization creates economic opportunities in the medical cannabis market. Legalization can create jobs, generate tax revenue, and encourage investment in research and development. This can help to drive innovation in the medical cannabis industry, leading to the development of new and more effective products. Countries that legalize medical cannabis can benefit from the economic and public health potential, and manage the legal and social implications. In 2018, the World Health Organization Expert Committee on Drug Dependence, conducted a review of cannabis and its derivatives, including cannabidiol (CBD) and tetrahydrocannabinol (THC), and recommended that cannabis and certain cannabis-related substances should be rescheduled under international drug control conventions to facilitate research into their potential therapeutic uses. Also, WHO stated that CBD has been shown to be effective in treating some forms of epilepsy and tetrahydrocannabinol (THC) may have therapeutic benefits for certain medical conditions such as chronic pain, nausea, and vomiting.

Growing Acceptance and Awareness About the Potential Benefits Drive the Market

Growing acceptance and awareness about the potential benefits of medical cannabis is leading to an increase in demand for medical cannabis in the market. Cannabis contains compounds called cannabinoids, which have been found to have various therapeutic properties for example, cannabinoids can help alleviate symptoms of chronic pain, nausea and vomiting, anxiety, and sleep disorders. In response, more countries and states are legalizing medical cannabis, which further drives the demand. Additionally, advancements in technology have made it easier to extract and produce cannabis-based products, making them more accessible to patients who need them. Therefore, the growing acceptance and awareness of medical cannabis are driving the demand for medical cannabis in the market.

Also, more countries and states legalize medical cannabis, more patients have access to medical cannabis. This has led to a significant increase in demand as patients seek alternative therapies to traditional medicines. Cannabis-based products are being marketed more effectively, with companies emphasizing their therapeutic properties and safety. This has led to increased consumer awareness and demand. The perception of cannabis has shifted in recent years, with more people accepting cannabis potential medical benefits. This has led to greater demand from patients who may have previously been reluctant to try medical cannabis. Therefore, the growing acceptance of people towards the use of medical cannabis is likely to fuel the medical cannabis market in the forecast period.

Medical cannabis has been found to have several potential benefits in treating various medical conditions such as Medical cannabis has shown to be effective in reducing chronic pain, including neuropathic pain, back pain, and arthritis. Cannabis-based products can be effective in reducing nausea and vomiting caused by chemotherapy, HIV/AIDS medications, and other medical treatments. Cannabinoids found in medical cannabis have been shown to reduce symptoms of anxiety and depression. As Per The Data Quoted By The National Conference Of State Legislatures, As of April 24, 2023, the District of Columbia, three territories, and 38 states permit the use of cannabis products for medical purposes.

Hence, the growing acceptance and awareness of medical cannabis has created a significant increase in demand for medical cannabis in the market, with patients seeking alternative therapies for a range of medical conditions.

Favorable Government initiatives and Policies Drive the Medical Cannabis Market Growth

Favorable government initiatives and policies drives the growth of the medical cannabis market as more and more countries and states legalize medical cannabis, there is a growing demand for products that contain cannabis and its derivatives. Government initiatives that support research and development of medical cannabis, provide funding for medical cannabis businesses, and streamline the regulatory process that contribute to the growth of the medical cannabis market.

In addition, government policies that allow for easier access to medical cannabis for patients and healthcare professionals, such as removing barriers to prescribing and dispensing, can help to drive the growth. This can lead to increased adoption of medical cannabis as a treatment option, which in turn can drive demand for related products and services. However, different countries and states have different policies and regulations regarding medical cannabis. Some may have strict requirements for licensing, testing, and quality control, while others may have more relaxed regulations. Therefore, the growth of the medical cannabis market can vary depending on the specific regulatory environment in a given region. According to the data quoted by Savills plc, the majority of the world's legal medicinal cannabis is produced in the UK. The UK output of cannabis-derived pharmaceuticals surged by nearly 500% between 2015 and 2017, reaching 235 tonnes, making it the largest global producer by a significant margin.

Market Segmentation

Global medical cannabis market is segmented based on product type, active ingredient, distribution channel, application, end user, and region. Based on product type, the medical cannabis market is segmented into buds/marijuana flower and cannabis extracts. Based on active ingredient, the medical cannabis market is segmented into Tetrahydrocannabinol (THC), Cannabidiol (CBD), and others. Based on distribution channel, the medical cannabis market is segmented into B2B and B2C. Based on application, the medical cannabis market is divided into chronic pain, mental disorders, cancer, epilepsy, and others. Based on end user, the medical cannabis market is segmented into pharmaceutical & biotechnology companies, academic & research institutions, and others. Based on region, the medical cannabis market is divided into North America, Europe, Asia Pacific, South America, Middle East & Africa.

Company Profiles

Canopy Growth Corporation., Aphria, Inc., Maricann Group, Inc., Tikun Olam - Cannabit Pharmaceuticals Ltd., MedReleaf. Corp., GW Pharmaceuticals plc., Cannabis Sativa, Inc., Medical Marijuana, Inc., Aurora Marijuana Inc., and Cronos Group Inc are some of the key players of global medical Cannabis market.

Report Scope:

In this report, global Medical Cannabis market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

  • Medical Cannabis Market, By Product Type:

Buds/Marijuana Flower

Cannabis Extracts

  • Medical Cannabis Market, By Active Ingredient:

Tetrahydrocannabinol (THC)

Cannabidiol (CBD)

Others

  • Medical Cannabis Market, By Distribution Channel:

B2B

B2C

  • Medical Cannabis Market, By Application:

Chronic Pain

Mental Disorders

Cancer

Epilepsy

Others

  • Medical Cannabis Market, By End User:

Pharmaceutical & Biotechnology Companies

Academic & Research Institutions

Others

  • Medical Cannabis Market, By Region:

North America

  • United States
  • Mexico
  • Canada

Europe

  • Germany
  • Malta
  • United Kingdom
  • France
  • Denmark
  • Italy
  • Spain

Asia-Pacific

  • Australia
  • China
  • Thailand
  • South Korea
  • India

South America

  • Brazil
  • Argentina
  • Colombia

Middle East & Africa

  • Lebanon
  • South Africa
  • Israel

Competitive landscape

Company Profiles: Detailed analysis of the major companies present in the global Medical Cannabis market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Product Code: 15430

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Medical Cannabis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
    • 6.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
    • 6.2.3. By Distribution Channel (B2B, B2C)
    • 6.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
    • 6.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
    • 6.2.6. By Region
    • 6.2.7. By Company (2022)
  • 6.3. Product Map
    • 6.3.1 By Product Type
    • 6.3.2 By Active Ingredient
    • 6.3.3 By Distribution Channel
    • 6.3.4 By Application
    • 6.3.5 By End User
    • 6.3.4 By Region

7. North America Medical Cannabis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
    • 7.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
    • 7.2.3. By Distribution Channel (B2B, B2C)
    • 7.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
    • 7.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
    • 7.2.6. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Medical Cannabis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Active Ingredient
        • 7.3.1.2.3. By Distribution Channel
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User Industry
    • 7.3.2. Canada Medical Cannabis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Active Ingredient
        • 7.3.2.2.3. By Distribution Channel
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User Industry
    • 7.3.3. Mexico Medical Cannabis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Active Ingredient
        • 7.3.3.2.3. By Distribution Channel
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User Industry

8. Europe Medical Cannabis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
    • 8.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
    • 8.2.3. By Distribution Channel (B2B, B2C)
    • 8.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
    • 8.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
    • 8.2.6. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Germany Medical Cannabis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Active Ingredient
        • 8.3.1.2.3. By Distribution Channel
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User Industry
    • 8.3.2. Malta Medical Cannabis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Active Ingredient
        • 8.3.2.2.3. By Distribution Channel
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User Industry
    • 8.3.3. United Kingdom Medical Cannabis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecasty
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Active Ingredient
        • 8.3.3.2.3. By Distribution Channel
        • 8.3.3.2.4. B y Application
        • 8.3.3.2.5. By End User Industry
    • 8.3.4. France Medical Cannabis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Active Ingredient
        • 8.3.4.2.3. By Distribution Channel
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User Industry
    • 8.3.5. Denmark Medical Cannabis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Active Ingredient
        • 8.3.5.2.3. By Distribution Channel
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User Industry
    • 8.3.6. Italy Medical Cannabis Market Outlook
      • 8.3.6.1. Market Size & Forecast
        • 8.3.6.1.1. By Value
      • 8.3.6.2. Market Share & Forecast
        • 8.3.6.2.1. By Product Type
        • 8.3.6.2.2. By Active Ingredient
        • 8.3.6.2.3. By Distribution Channel
        • 8.3.6.2.4. By Application
        • 8.3.6.2.5. By End User Industry
    • 8.3.7. Spain Medical Cannabis Market Outlook
      • 8.3.7.1. Market Size & Forecast
        • 8.3.7.1.1. By Value
      • 8.3.7.2. Market Share & Forecast
        • 8.3.7.2.1. By Product Type
        • 8.3.7.2.2. By Active Ingredient
        • 8.3.7.2.3. By Distribution Channel
        • 8.3.7.2.4. By Application
        • 8.3.7.2.5. By End User Industry

9. Asia-Pacific Medical Cannabis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
    • 9.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
    • 9.2.3. By Distribution Channel (B2B, B2C)
    • 9.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
    • 9.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
    • 9.2.6. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. Australia Medical Cannabis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Active Ingredient
        • 9.3.1.2.3. By Distribution Channel
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User Industry
    • 9.3.2. China Medical Cannabis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Active Ingredient
        • 9.3.2.2.3. By Distribution Channel
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User Industry
    • 9.3.3. Thailand Medical Cannabis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Active Ingredient
        • 9.3.3.2.3. By Distribution Channel
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User Industry
    • 9.3.4. South Korea Medical Cannabis Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Product Type
        • 9.3.4.2.2. By Active Ingredient
        • 9.3.4.2.3. By Distribution Channel
        • 9.3.4.2.4. By Application
        • 9.3.4.2.5. By End User Industry
    • 9.3.5. India Medical Cannabis Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Product Type
        • 9.3.5.2.2. By Active Ingredient
        • 9.3.5.2.3. By Distribution Channel
        • 9.3.5.2.4. By Application
        • 9.3.5.2.5. By End User Industry

10. South America Medical Cannabis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
    • 10.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
    • 10.2.3. By Distribution Channel (B2B, B2C)
    • 10.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
    • 10.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Medical Cannabis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Active Ingredient
        • 10.3.1.2.3. By Distribution Channel
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User Industry
    • 10.3.2. Argentina Medical Cannabis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Active Ingredient
        • 10.3.2.2.3. By Distribution Channel
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User Industry
    • 10.3.3. Colombia Medical Cannabis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Active Ingredient
        • 10.3.3.2.3. By Distribution Channel
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User Industry

11. Middle East and Africa Medical Cannabis Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
    • 11.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
    • 11.2.3. By Distribution Channel (B2B, B2C)
    • 11.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
    • 11.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
    • 11.2.6. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. Lebanon Medical Cannabis Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Product Type
        • 11.3.1.2.2. By Active Ingredient
        • 11.3.1.2.3. By Distribution Channel
        • 11.3.1.2.4. By Application
        • 11.3.1.2.5. By End User Industry
    • 11.3.2. South Africa Medical Cannabis Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Product Type
        • 11.3.2.2.2. By Active Ingredient
        • 11.3.2.2.3. By Distribution Channel
        • 11.3.2.2.4. By Application
        • 11.3.2.2.5. By End User Industry
    • 11.3.3. Israel Medical Cannabis Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Product Type
        • 11.3.3.2.2. By Active Ingredient
        • 11.3.3.2.3. By Distribution Channel
        • 11.3.3.2.4. By Application
        • 11.3.3.2.5. By End User Industry

12. Market Dynamics

  • 12.1. Drivers
    • 12.1.1 High prevalence of Chronic
    • 12.1.2 Legalization of Medical Cannabis
  • 12.2. Challenges
    • 12.2.1 High cost and not always readily available
    • 12.2.2 Less acceptance by the Consumer

13. Market Trends & Developments

  • 13.1. New Product Development
  • 13.2. Increasing use of Medical Cannabis by the medicinal and pharmaceutical industries.

14. Global Medical Cannabis Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Business Overview
  • 16.2. Product Offerings
  • 16.3. Recent Developments
  • 16.4. Financials (As Reported)
  • 16.5. Key Personnel
  • 16.6. SWOT Analysis
      • 16.6.1.1. Canopy Growth Corporation
      • 16.6.1.2. Aphria, Inc.
      • 16.6.1.3. Maricann Group, Inc
      • 16.6.1.4. Tikun Olam - Cannabit Pharmaceuticals Ltd
      • 16.6.1.5. MedReleaf. Corp
      • 16.6.1.6. GW Pharmaceuticals plc.
      • 16.6.1.7. Cannabis Sativa, Inc.
      • 16.6.1.8. Medical Marijuana, Inc
      • 16.6.1.9. Aurora Marijuana Inc.
      • 16.6.1.10. Cronos Group Inc.

17. Strategic Recommendation

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!